What is an intraductal papillary mucinous neoplasm (IPMN)?
An intraductal papillary mucinous neoplasm, usually shortened to IPMN, is a growth that forms inside the ducts of the pancreas. The pancreas is a gland that sits behind the stomach. A network of small tubes, called ducts, carries digestive juice from the gland into the bowel.
In an IPMN, the cells lining these ducts grow in small finger-like folds (papillae) and produce large amounts of mucus. The mucus collects and stretches the duct, so on a scan an IPMN looks like a fluid-filled cyst.
IPMNs are not cancer at first. They are described as precancerous: most stay harmless for many years, but some slowly change through stages of low-grade dysplasia, then high-grade dysplasia, and finally invasive cancer. The aim of care is to find the small number that are likely to become dangerous and remove them, while sparing everyone else an unnecessary operation.
IPMNs are now found much more often than in the past. Most are discovered by chance on CT or MRI scans done for other reasons (Gardner, Park and Allen, 2024). They are most common in people in their 60s and 70s. They make up roughly a quarter of cystic tumours of the pancreas (Jablonska, Szmigiel and Mrowiec, 2021).
Doctors manage IPMNs with either regular scans (surveillance) or surgery. The choice depends on where the IPMN sits in the duct system, its size, how fast it grows, and whether it shows warning signs on imaging.
1. Key facts at a glance
| Feature | Details |
|---|---|
| What it is | A mucus-producing growth inside the pancreatic ducts |
| Cancer or not | A precancerous lesion; a minority become invasive cancer |
| How common | Very common on scans in older adults; about 1 in 4 cystic pancreatic tumours |
| Typical age | Usually 60-80 |
| How it is found | Most often by chance on a scan |
| Main types | Main-duct, branch-duct and mixed type |
| Highest-risk type | Main-duct IPMN |
| Main management | Surveillance with MRI or endoscopic ultrasound, or surgery |
| Outlook | Excellent for low-risk IPMNs; depends on stage if cancer develops |
2. Types of IPMN
By location in the duct system
The pancreas has one main duct running along its length, with many smaller branch ducts feeding into it.
| Type | Where it grows | Cancer risk | Usual approach |
|---|---|---|---|
| Main-duct IPMN | The main pancreatic duct, which becomes widened | High | Surgery is usually advised if fit |
| Branch-duct IPMN | One or more side branches | Low for most | Surveillance unless warning signs appear |
| Mixed-type IPMN | Both main and branch ducts | Similar to main-duct | Managed like main-duct IPMN |
Branch-duct IPMNs are by far the most common, and many people have several small ones.
By degree of change in the cells
When an IPMN is removed, the pathologist grades how abnormal the cells are.
| Grade | Meaning |
|---|---|
| Low-grade dysplasia | Mild changes; not cancer |
| High-grade dysplasia | Marked changes; the final step before invasive cancer |
| IPMN with associated invasive carcinoma | Cancer cells have broken out of the duct into the pancreas |
By cell pattern
Pathologists also describe the epithelial subtype, which helps predict behaviour.
| Subtype | Notes |
|---|---|
| Gastric | Most common, usually in branch-duct IPMNs; often low grade |
| Intestinal | Usually main-duct; may lead to colloid (mucinous) carcinoma |
| Pancreatobiliary | Less common; linked to more aggressive tubular cancers |
A related tumour, the intraductal oncocytic papillary neoplasm, used to be counted as an IPMN subtype but is now regarded as a separate entity.
How IPMN compares with other pancreatic cysts
| Cyst type | Cancer potential | Notes |
|---|---|---|
| IPMN | Yes | Connects with the duct system |
| Mucinous cystic neoplasm | Yes | Mainly in women; usually in the body or tail |
| Serous cystadenoma | Almost none | Often has a honeycomb appearance |
| Pseudocyst | None | Follows pancreatitis; not a tumour |
| Solid pseudopapillary neoplasm | Low-grade cancer | Mostly in young women |
3. Causes and risk factors
The cause of most IPMNs is unknown. The cells usually carry changes in genes such as KRAS and GNAS, which arise during life and are not inherited.
| Factor | Notes |
|---|---|
| Older age | The main risk factor; IPMNs become more common with each decade |
| Family history of pancreatic cancer | Some families have more IPMNs and pancreatic cancers |
| Inherited syndromes | For example Peutz-Jeghers syndrome or familial adenomatous polyposis, rarely |
| Smoking | May increase the risk that an IPMN becomes cancer |
| Diabetes and obesity | Possible links; evidence is mixed |
People with an IPMN also have a slightly higher risk of a separate pancreatic cancer elsewhere in the gland. This is one reason why follow-up looks at the whole pancreas, not just the cyst itself (Ohtsuka et al., 2024).
4. How does it look
On scans
| Feature | What it means |
|---|---|
| Small round cyst | Typical branch-duct IPMN |
| Cluster of cysts, like grapes | Several dilated branch ducts |
| Communication with the main duct | Supports the diagnosis of IPMN |
| Widened main duct | Suggests main-duct or mixed-type IPMN |
| Solid nodule inside the cyst | A warning sign of high-grade change or cancer |
| Thickened cyst wall | A worrying feature |
MRI with MRCP, a special MRI that shows the ducts, is the most useful single test for most IPMNs (Jablonska, Szmigiel and Mrowiec, 2021).
Through the endoscope
During an ERCP or a special endoscopy, the opening of the main duct into the bowel can sometimes be seen to be widened and leaking thick mucus. This has been compared to a “fish-mouth” appearance.
Under the microscope
| Feature | Description |
|---|---|
| Lining | Tall mucus-producing cells |
| Architecture | Papillary folds projecting into the duct |
| Duct contents | Thick mucus |
| Grade | Low-grade or high-grade dysplasia |
| Invasion | Present only if cancer has developed |
5. Symptoms
Most people have none
The majority of IPMNs cause no symptoms and are found by chance.
Possible symptoms
| Symptom | Possible cause |
|---|---|
| Upper abdominal pain | Blockage of the duct by mucus |
| Attacks of pancreatitis | Mucus blocking the flow of digestive juice |
| Back pain | Larger lesions or invasive cancer |
| Weight loss | Poor digestion or cancer |
| Pale, oily stools | Reduced digestive enzymes |
| New diabetes | Damage to the insulin-producing tissue |
| Yellow skin and eyes (jaundice) | Blockage of the bile duct; a warning sign |
When to seek medical advice
Contact your doctor promptly if you have an IPMN and develop jaundice, unexplained weight loss, new or worsening diabetes, repeated pancreatitis or persistent abdominal or back pain. These may mean that the IPMN has changed.
6. Diagnosis
| Test | Purpose |
|---|---|
| MRI with MRCP | Shows the cyst, the ducts and any nodules |
| CT scan | Useful for staging and planning surgery |
| Endoscopic ultrasound (EUS) | A close-up scan from inside the stomach; shows nodules well |
| EUS-guided fine needle aspiration | Samples cyst fluid for cells, mucus and markers |
| Cyst fluid tests | CEA, glucose and DNA tests such as KRAS and GNAS |
| CA 19-9 blood test | A raised level may point to cancer |
| HbA1c or glucose | Checks for new diabetes |
Warning signs that guide treatment
International and European guidelines group imaging findings into high-risk and worrying features (European Study Group, 2018; Ohtsuka et al., 2024). The latest Kyoto guidelines also take into account endoscopic ultrasound findings and cytology.
| Category | Examples |
|---|---|
| High-risk features (surgery usually advised) | Jaundice caused by the cyst; enhancing solid component or nodule of 5 mm or more; main duct 10 mm or wider; suspicious or malignant cells on cytology |
| Worrying features (closer assessment, often EUS) | Cyst 3 cm or more; smaller enhancing nodule; thickened wall; main duct 5-9 mm; rapid growth; raised CA 19-9; pancreatitis; new diabetes |
| No warning features | Surveillance with regular scans |
The European guideline recommends a conservative approach for symptom-free IPMNs smaller than 4 cm without an enhancing nodule (European Study Group, 2018).
7. Treatment
Surveillance
Most branch-duct IPMNs are watched with MRI, sometimes alternating with endoscopic ultrasound.
| Cyst size and features | Typical interval |
|---|---|
| Under 2 cm, no warning features | Every 6-12 months at first, then every 1-2 years |
| 2-3 cm | Every 6-12 months |
| Over 3 cm or worrying features | Every 3-6 months, often with EUS |
Intervals differ between guidelines, so your team will tailor the plan to you.
The Kyoto guidelines discuss whether scans can be stopped. For small branch-duct IPMNs that have not changed after five years, one option is to stop surveillance; another is to continue, mainly to look for a separate pancreatic cancer (Ohtsuka et al., 2024). For people who could not have surgery, surveillance may have little purpose.
Surgery
| Operation | When it is used |
|---|---|
| Pancreaticoduodenectomy (Whipple procedure) | IPMN in the head of the pancreas |
| Distal pancreatectomy | IPMN in the body or tail, often with removal of the spleen |
| Total pancreatectomy | When the IPMN involves the whole duct; causes lifelong diabetes |
| Limited (parenchyma-sparing) resections | Selected small lesions |
During surgery, the cut edge of the pancreas is often checked under the microscope while the patient is still asleep, so that more can be removed if abnormal cells remain.
If invasive cancer is found
Invasive cancer arising in an IPMN is treated like pancreatic cancer, usually with chemotherapy such as FOLFIRINOX or gemcitabine-based combinations before or after surgery. Colloid carcinoma, a mucus-rich type, tends to behave better than ordinary tubular adenocarcinoma.
Endoscopic treatment
For people who are not fit for surgery, newer techniques such as EUS-guided ablation are being explored, although they are not yet standard (Gardner, Park and Allen, 2024).
Side effects of surgery
| Effect | Notes |
|---|---|
| Pancreatic leak (fistula) | The most common complication; usually settles with drains |
| Delayed stomach emptying | Common after a Whipple; improves over weeks |
| Diabetes | Possible after any resection; certain after total pancreatectomy |
| Poor digestion | Treated with pancreatic enzyme capsules taken with meals |
| Infection after spleen removal | Prevented with vaccinations and, sometimes, antibiotics |
8. Outlook (prognosis)
| Situation | Usual outlook |
|---|---|
| Small branch-duct IPMN without warning features | Excellent; very low yearly risk of cancer |
| IPMN removed with low- or high-grade dysplasia | Excellent; follow-up still needed |
| IPMN with invasive cancer, early stage | Better than ordinary pancreatic cancer |
| IPMN with advanced invasive cancer | Similar to other advanced pancreatic cancers |
For most people, an IPMN is a lifelong condition to be monitored rather than a dangerous disease.
9. Follow-up
| Situation | What follow-up involves |
|---|---|
| Under surveillance | Regular MRI or EUS, with blood tests as needed |
| After removal of a non-invasive IPMN | Scans of the remaining pancreas, because new IPMNs or cancer can develop |
| After removal of an invasive cancer | Cancer follow-up with CT scans and CA 19-9 |
| After pancreatic surgery | Checks for diabetes, digestion and nutrition |
The European guideline advises lifelong follow-up for people with an IPMN who would be fit for surgery (European Study Group, 2018).
10. Living with an IPMN
- Keep your scan appointments and know when the next one is due
- Stop smoking, which raises the risk of pancreatic cancer
- Limit alcohol to protect the pancreas
- Watch for warning symptoms such as jaundice, weight loss and new diabetes
- Take enzyme capsules with meals if you have had surgery and your team prescribes them
- Tell relatives if there is a family history of pancreatic cancer, as they may benefit from advice
- Ask for support if waiting for scan results makes you anxious
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is an IPMN cancer? | No, it is a precancerous growth; only a minority become cancer |
| Why was it found by chance? | Modern scans pick up many small cysts that cause no symptoms |
| Do I need surgery? | Most branch-duct IPMNs do not; main-duct IPMNs and those with warning signs often do |
| Can I have more than one? | Yes, multiple small IPMNs are common |
| Will it ever go away? | Usually not, but most stay stable |
| Can surveillance stop? | Possibly, for small unchanged branch-duct IPMNs after several years; discuss this with your team |
| Will diet change it? | No diet is known to shrink an IPMN, but a healthy lifestyle protects the pancreas |
| Is it inherited? | Usually not, unless there is a strong family history |
12. Questions to ask your care team
- Is my IPMN main-duct, branch-duct or mixed?
- Does it have any high-risk or worrying features?
- How often will I need scans, and which type?
- Would you recommend endoscopic ultrasound or cyst fluid testing?
- If surgery is advised, which operation would I need and what are the risks?
- Will I need enzyme capsules or treatment for diabetes afterwards?
- Is there a point when surveillance can stop?
Resources
- European Study Group on Cystic Tumours of the Pancreas (2018) ‘European evidence-based guidelines on pancreatic cystic neoplasms’, Gut, 67(5), pp. 789-804.
- Gardner, T.B., Park, W.G. and Allen, P.J. (2024) ‘Diagnosis and management of pancreatic cysts’, Gastroenterology, 167(3), pp. 454-468.
- Jablonska, B., Szmigiel, P. and Mrowiec, S. (2021) ‘Pancreatic intraductal papillary mucinous neoplasms: current diagnosis and management’, World Journal of Gastrointestinal Oncology, 13(12), pp. 1880-1895.
- Ohtsuka, T. et al. (2024) ‘International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas’, Pancreatology, 24(2), pp. 255-270.
- National Cancer Institute (2026) Pancreatic Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.